{"organizations": [], "uuid": "c975daed8968971d90e9bf31375518049a081088", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180411.html", "section_title": "Archive News &amp; Video for Wednesday, 11 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-zhenxing-biopharmaceutical-chemica/brief-zhenxing-biopharmaceutical-chemical-unit-receives-approval-for-drug-clinical-trial-idUSL3N1RO3MS", "country": "US", "domain_rank": 408, "title": "BRIEF-Zhenxing Biopharmaceutical & Chemical unit receives approval for drug clinical trial", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.967, "site_type": "news", "published": "2018-04-11T16:12:00.000+03:00", "replies_count": 0, "uuid": "c975daed8968971d90e9bf31375518049a081088"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-zhenxing-biopharmaceutical-chemica/brief-zhenxing-biopharmaceutical-chemical-unit-receives-approval-for-drug-clinical-trial-idUSL3N1RO3MS", "ord_in_thread": 0, "title": "BRIEF-Zhenxing Biopharmaceutical & Chemical unit receives approval for drug clinical trial", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-zhenxing biopharmaceutical & chemical", "sentiment": "negative"}, {"name": "zhenxing biopharmaceutical & chemical co ltd", "sentiment": "negative"}, {"name": "beijing headline news", "sentiment": "none"}, {"name": "china food and drug administration", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 11(Reuters) - Zhenxing Biopharmaceutical & Chemical Co Ltd\n* Says coâ€™s Guangdong-based wholly owned biopharmaceutical unit received approval for drug clinical trial for Human Fibrinogen, from China Food and Drug Administration\nSource text in Chinese: goo.gl/9eN1Q8\nFurther company coverage: (Beijing Headline News)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "https://goo.gl/9eN1Q8", "https://instagram.com/reuters/"], "published": "2018-04-11T16:12:00.000+03:00", "crawled": "2018-04-12T14:13:58.005+03:00", "highlightTitle": ""}